Transcriptomic Responses for the Identification of Pathogens (TRiP)

University of Sheffield

Status: Enrolling

Conditions: Fever; Typhoid; Paratyphoid Fever; Acute Febrile Illness; Enteric Fever

Treatments: Diagnostic Test: 5-gene transcription signature

Study type: Observational

Funder types: Other

Identifiers

NCT04878549

157365

Details and patient eligibility

About

Acute undifferentiated febrile infection (AUFI) is a common presenting syndrome in low-resource settings and better diagnostics are urgently needed to improve patient management and guide disease prevention interventions. Assessment of the host gene expression response to infection in endemic populations has demonstrated significant promise as a new approach to identifying patients with enteric fever and for potential in differentiating between other causes of AUFI. Signatures identified through new data analytic techniques could be developed into a point-of-care test for use in endemic settings.

In this multisite diagnostic evaluation study we will collect prospective clinical, laboratory and diagnostic data from two endemic settings to evaluate host gene expression signatures for detecting enteric fever and for determining the cause of AUFI in LMIC settings.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 2 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

FEBRILE ADULTS- INCLUSION CRITERIA

• Age greater than or equal to 15 years and less than or equal to 65 years

• Participant is willing and they and/or an appropriate guardian/relative/representative is able to give informed consent for participation in the study and a follow-up (telephone) discussion at 14 days

• And either:

  1. Febrile illness without localising features (see 'exclusion criteria' and 'screening' sections) where fever is defined as:

     • documented tympanic/rectal temperature of ≥ 38°C or an axillary/oral temperature of ≥ 37.8°C, or a reported fever within the last 24 hours and
     • Reported duration of fever 3-14 days or

  2. Recently confirmed blood culture indicating enteric fever (confirmed within the previous 5 days)

• They may have had recent exposure to antimicrobials.

FEBRILE ADULTS- EXCLUSION CRITERIA

• The participant may not enter the study if ANY of the following apply:

• Unable to provide informed consent and no next of kin is willing and able to provide informed consent.

• For patients with febrile illness (included in (1) above): Any history or clinical suspicion of:

  • Rheumatological or connective tissue disorder (e.g. Rheumatoid arthritis)
  • Autoimmune condition (e.g. Autoimmune Hepatitis)
  • Malignancy
  • Active treatment with immunomodulating medications, or for tuberculosis (pulmonary or extrapulmonary) or any other chronic infection.

• Pregnancy (breast feeding mothers will NOT be excluded)

• No hospitalisation for more than 48 hours in the last 4 weeks

• Vaccination within 4 weeks prior to current admission

• Localising signs or symptoms of infection sufficient to diagnose the likely cause of acute febrile illness and thus prevent it from being 'undifferentiated.'

CONTROLS- INCLUSION CRITERIA

• Participant is willing and they are (and in 15-18 year olds, a guardian is) able to give informed consent for participation in the study
• Age greater than or equal to 15 years and less than or equal to 65 years
• They live outside of the normal/local catchment area for each hospital site
• Afebrile (as defined by no reported fever and temperature ≤ 38°C or an axillary/oral temperature of ≤ 37.8°C).

CONTROLS- EXCLUSION CRITERIA

• The participant may not enter the study if ANY of the following apply:

• Unable to provide informed consent and no next of kin (or parent/guardian in the case of a minor) is willing and able to provide informed consent.

• Current treatment for or prior history, or clinical suspicion of:

  • Rheumatological or connective tissue disorder
  • Autoimmune condition
  • Malignancy
  • Active treatment for tuberculosis (pulmonary or extrapulmonary) or clinical suspicion of active tuberculosis. Previous completed treatment is not a reason for exclusion.
  • Active treatment with immunomodulating medications or any other chronic infection.

• Pregnant (breast feeding mothers will NOT be excluded)

• Hospitalisation within 4 weeks of recruitment

• Vaccination within 4 weeks prior to recruitment

• Antimicrobial use within 4 weeks of recruitment

• Participant reports feeling more unwell than usual on the day of enrolment.

EXPLORATORY AIMS- PAEDIATRIC CRITERIA; INCLUSION CRITERIA

• Age greater than or equal to 2 years and less than 15 years
• As above for adult participants.

EXPLORATORY AIMS- PAEDIATRIC CRITERIA; EXCLUSION CRITERIA

• Parent/guardian is unwilling, and/or patient aged 8 to 14 years is unwilling to assent to provide informed consent.
• As above for adult participants.

Trial design

2,000 participants in 3 patient groups

Febrile Adults

Description:

1200 adult participants (15 to 65 years old) with a febrile illness without localising features and reported duration of 3-14 days.

Treatment:

Diagnostic Test: 5-gene transcription signature

Controls

Description:

400 afebrile, healthy adult participants (15 to 65 years old).

Treatment:

Diagnostic Test: 5-gene transcription signature

Febrile Children

Description:

400 child participants (2 to 14 years old) with a febrile illness without localising features and reported duration of 3-14 days. This is an exploratory arm of the study.

Treatment:

Diagnostic Test: 5-gene transcription signature